<DOC>
	<DOCNO>NCT00486109</DOCNO>
	<brief_summary>This study investigate wearability usability I-PORT™ Injection Port ( I-PORT™ ) , new disposable injection port prescribe medication inject subcutaneously standard syringe pen . Additional investigation compare subject opinion towards use I-PORT™ device compare standard injection therapy .</brief_summary>
	<brief_title>A Prospective , Randomized , Parallel Crossover Study Demonstrating Subject Wearability Usability I-Port Injection Port</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>Male female subject , 1470 year age , type 1 type 2 diabetes mellitus minimum six ( 6 ) month Subjects must utilize regimen least two ( 2 ) injection daily either Novolin® , Humulin® , NovoLog® , Humalog® Apidra® one ( 1 ) injection Lantus® daily use standard syringe insulin pen Current regimen intensify insulin therapy ( define separate injection basal prandial insulin least three ( 3 ) insulin injection per day ) minimum three ( 3 ) month Body Mass Index &lt; 35 kg/m2 HbA1c ≤ 10 % If medication ( oral antidiabetic agent ) addition insulin take screening , subject must stable regimen define continue use dose medication period least three ( 3 ) month prior study enrollment Subjects must willing provide write informed consent Use Continuous Subcutaneous Insulin Infusion ( CSII ) time within precede three ( 3 ) month History current diagnosis chronic disease view PI would interfere adequate involvement completion requirement study Use short term chronic steroid within two ( 2 ) month entry study likelihood might require conduct study Use hydrochlorthiazide dose &gt; 25 mg daily Use betablocker drug Regular preprandial dos SC insulin &gt; 30 IU per meal Intake drug herbal preparation , evaluation PI , may interfere interpretation clinical study result know cause clinically relevant interference insulin action , glucose utilization ability detect recover hypoglycemia ( e.g. , systemic steroid ) History know hypersensitivity plastic polymer Treatment investigational drug within two ( 2 ) month prior enrollment study Progressive fatal disease History malignancy within five ( 5 ) year study entry ( basal cell carcinoma ) Evidence severe secondary complication diabetes ( neuropathy , nephropathy evidence creatinine &gt; 1.5 mg/dL female &gt; 1.8 mg/dL male , grade III IV retinopathy severe peripheral vascular disease ) Evidence gastroparesis , orthostatic hypotension hypoglycemia unawareness ( autonomic neuropathy ) Myocardial infarction stroke within precede six ( 6 ) month Positive hepatitis B ( HBsAg ) and/or hepatitis C ( Hep C AB ) serology and/or positive HIV serology History presence clinically significant cardiovascular , hepatic ( evidenced ALT AST &gt; 3 time upper limit normal ) , gastrointestinal , neurological infectious disorder capable alter absorption , metabolism elimination drug , constitute significant risk factor use study device Anemia ( hemoglobin level &lt; 11 g/dL female &lt; 12 g/dL male ) Pregnancy , lactation , intention become pregnant Female subject childbearing potential practicing inadequate birth control ( adequate birth control define use oral Regular alcohol intake great 18 units*/week , subject unwilling stop alcohol duration study ( * 1 unit = 8 g ethanol , ¼ liter beer 1 glass wine 1 ounce spirit ) PI clinical site personnel directly affiliate study immediate family . Immediate family define spouse , parent , child sibling , whether biological legally adopt A lack compliance ( include inability maintain minimum 75 % compliance study device administration ) reason , opinion PI may preclude participation subject study</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Diabetes</keyword>
</DOC>